On Invalid Date, Evogene (NASDAQ: EVGN) reported Q3 2023 earnings per share (EPS) of -$0.08, up 50% year over year. Total Evogene earnings for the quarter were -$3.98 million. In the same quarter last year, Evogene's earnings per share (EPS) was -$0.16.
As of Q4 2023, Evogene's earnings has grown year over year. Evogene's earnings in the past year totalled -$20.28 million.
What was EVGN's revenue last quarter?
On Invalid Date, Evogene (NASDAQ: EVGN) reported Q3 2023 revenue of $3.77 million up 708.37% year over year. In the same quarter last year, Evogene's revenue was $466.00 thousand.
What was EVGN's revenue growth in the past year?
As of Q4 2023, Evogene's revenue has grown 331.52% year over year. This is 220.95 percentage points higher than the US Biotechnology industry revenue growth rate of 110.58%. Evogene's revenue in the past year totalled $5.72 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.